A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
Abstract HER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to circumvent the limited efficacy observed for HER3-blocking antibodies in clinical trials. I...
Guardado en:
Autores principales: | Nadine Aschmoneit, Sophia Steinlein, Lennart Kühl, Oliver Seifert, Roland E. Kontermann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d989d218664f4b1999818ee6967f204d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
por: Enrique J. Arenas, et al.
Publicado: (2021) -
Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice
por: Yoshiro Fushimi, et al.
Publicado: (2021) -
Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Aleksandra Rodak, et al.
Publicado: (2021) -
Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Kiyohiko Takahashi, et al.
Publicado: (2018) -
DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db mice.
por: Peng Sun, et al.
Publicado: (2013)